+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis

Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis

Annals of Neurology 83(2): 258-268

The neurodegenerative disease, amyotrophic lateral sclerosis (ALS), is a heterogeneous clinical syndrome involving multiple molecular pathways. The development of biomarkers for use in therapeutic trials is a priority. We sought to use a high-throughput proteomic method to identify novel biomarkers in individual cerebrospinal fluid (CSF) samples. Liquid chromatography/tandem mass spectrometry with label-free quantification was used to identify CSF proteins using samples from a well-characterized longitudinal cohort comprising patients with ALS (n = 43), the upper motor neuron variant, primary lateral sclerosis (PLS; n = 6), and cross-sectional healthy (n = 20) and disease controls (Parkinsons' disease, n = 20; ALS mimic disorders, n = 12). Three macrophage-derived chitinases showed increased abundance in ALS: chitotriosidase (CHIT1), chitinase-3-like protein 1 (CHI3L1), and chitinase-3-like protein 2 (CHI3L2). Elevated CHI3L1 was common to ALS and PLS, whereas CHIT1 and CHI3L2 levels differed. Chitinase levels correlated with disease progression rate (CHIT1, r = 0.56, p < 0.001; CHI3L1, r = 0.31; p = 0.028; CHI3L2, r = 0.29, p = 0.044). CHIT1, CHI3L1, and CHI3L2 levels correlated with phosphorylated neurofilament heavy chain (pNFH; r = 0.62, p < 0.001; r = 0.49, p < 0.001; r = 0.41, p < 0.001). CHI3L1 levels, but not CHIT1 or CHI3L2, increased over time in those with low initial levels (gradient = 0.005 log abundance units/month, p = 0.001). High CHIT1 was associated with shortened survival (hazard ratio [HR] 2.84; p = 0.009). Inclusion of pNFH in survival models left only an association of pNFH and survival (HR 1.26; p = 0.019). Neuroinflammatory mechanisms have been consistently implicated through various experimental paradigms. These results support a key role for macrophage activity in ALS pathogenesis, offering novel target engagement and pharmacodynamic biomarkers for neuroinflammation-focused ALS therapy. Ann Neurol 2018;83:258-268.

(PDF emailed within 0-6 h: $19.90)

Accession: 053832041

Download citation: RISBibTeXText

PMID: 29331073

DOI: 10.1002/ana.25143

Related references

Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex. Journal of Neurodegenerative Diseases 2013: 679089, 2013

Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. Journal of Neurochemistry 95(5): 1461-1471, 2005

Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Review of Proteomics 14(9): 769-777, 2017

Proteomic profiling of cerebrospinal fluid to identify diagnostic biomarkers for amyotrophic lateral sclerosis. FASEB Journal 18(4-5): Abst 151 5, 2004

Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients. Neuromolecular Medicine 18(4): 551-560, 2016

Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid. Bmc Medical Genomics 12(1): 7-7, 2019

Cerebrospinal fluid biomarkers for Alzheimer's disease in patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis with the C9ORF72 repeat expansion. Dementia and Geriatric Cognitive Disorders 39(5-6): 287-293, 2015

Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis. Journal of Proteome Research 14(11): 4486-4501, 2016

Increased cerebrospinal fluid levels of cytokines monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1β (MIP-1β) in patients with amyotrophic lateral sclerosis. Neurologia 2017, 2017

Cerebrospinal fluid cytotoxicity in lateral amyotrophic sclerosis. Neurologia 25(6): 364-373, 2011

Cerebrospinal fluid filtration in amyotrophic lateral sclerosis. European Journal of Neurology 6(5): 597-600, Sept, 1999

Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis. Neuroscience Letters 416(3): 257-260, 2007

Cerebrospinal fluid proteins in the course of amyotrophic lateral sclerosis. Revue Neurologique 125(5): 393-400, 1971

Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. Journal of Neurology 231(2): 75-78, 1984

Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics 14(1): 119-134, 2016